Bleeding Risk With Ischemic Stroke Therapy—Reply
暂无分享，去创建一个
[1] Geoff Cohen,et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.
[2] David J. Gladstone,et al. Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated , 2009, Stroke.
[3] Adnan I. Qureshi,et al. Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .
[4] Achim Gass,et al. Leukoaraiosis Is a Risk Factor for Symptomatic Intracerebral Hemorrhage After Thrombolysis for Acute Stroke , 2006 .
[5] P. Adeleine,et al. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[6] G. D. Graham,et al. Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical Practice: A Meta-Analysis of Safety Data , 2003, Stroke.